Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Human Papillomavirus Infections-Pipeline Review, H1 2015

Human Papillomavirus Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Human Papillomavirus Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Human Papillomavirus Infections-Pipeline Review, H1 2015', provides an overview of the Human Papillomavirus Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Human Papillomavirus Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Human Papillomavirus Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Human Papillomavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Human Papillomavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Human Papillomavirus Infections Overview 9

Therapeutics Development 10

Pipeline Products for Human Papillomavirus Infections-Overview 10

Pipeline Products for Human Papillomavirus Infections-Comparative Analysis 11

Human Papillomavirus Infections-Therapeutics under Development by Companies 12

Human Papillomavirus Infections-Therapeutics under Investigation by Universities/Institutes 16

Human Papillomavirus Infections-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Human Papillomavirus Infections-Products under Development by Companies 20

Human Papillomavirus Infections-Products under Investigation by Universities/Institutes 23

Human Papillomavirus Infections-Companies Involved in Therapeutics Development 24

3M Drug Delivery Systems 24

Admedus Ltd 25

Agilvax, Inc. 26

Anaconda Pharma 27

Beijing Minhai Biotechnology Co., Ltd 28

Bharat Biotech International Limited 29

Biogenomics Limited 30

BioMAS Ltd. 31

Chong Kun Dang Pharmaceutical Corp. 32

Chongqing Zhifei Biological Products Co., Ltd. 33

Crucell N.V. 34

Cutanea Life Sciences 35

EpiPharm AG 36

FluGen, Inc. 37

Foamix Pharmaceuticals Ltd. 38

G&E Herbal Biotechnology Co., Ltd. 39

Genticel S.A. 40

Helix BioPharma Corp. 41

Immunservice GmbH 42

Indian Immunologicals Limited 43

LEO Pharma A/S 44

MediGene AG 45

NanoViricides, Inc. 46

Nielsen Biosciences, Inc. 47

Novan, Inc. 48

Shanghai Zerun Biotechnology Co., Ltd. 49

Spider Biotech 50

Starpharma Holdings Limited 51

Takeda Pharmaceutical Company Limited 52

Vaxart, Inc. 53

ViroStatics, srl 54

Human Papillomavirus Infections-Therapeutics Assessment 55

Assessment by Monotherapy Products 55

Assessment by Combination Products 56

Assessment by Target 57

Assessment by Mechanism of Action 59

Assessment by Route of Administration 61

Assessment by Molecule Type 63

Drug Profiles 65

(digoxin + furosemide)-Drug Profile 65

854-A-Drug Profile 66

A-101-Drug Profile 67

AP-611074-Drug Profile 68

AS-101-Drug Profile 69

astodrimer-Drug Profile 71

AV2-DM-Drug Profile 73

AX-03-Drug Profile 74

Candida Albicans Antigen-Drug Profile 75

Cell Therapy for Human Papillomavirus Infection-Drug Profile 76

CKD-12201-Drug Profile 77

Drugs for HPV-Drug Profile 78

EPI-N06-Drug Profile 79

GBV-015-Drug Profile 80

HerpeCide-I-Drug Profile 81

HPV virus like particle vaccine-Drug Profile 82

HTI-1968-Drug Profile 83

human papilloma virus [types 16, 18] (bivalent) virus like particle vaccine-Drug Profile 84

human papilloma virus vaccine-Drug Profile 85

human papilloma virus vaccine-Drug Profile 86

human papilloma virus vaccine [types 16 and 18]-Drug Profile 87

human papillomavirus (multivalent) vaccine-Drug Profile 88

human papillomavirus (tetravalent) vaccine-Drug Profile 89

human papillomavirus [serotypes 16, 31] virus like particle vaccine-Drug Profile 90

human papillomavirus vaccine-Drug Profile 91

human papillomavirus vaccine-Drug Profile 92

human papillomavirus vaccine-Drug Profile 93

human papillomavirus vaccine-Drug Profile 94

human papillomavirus vaccine-Drug Profile 95

human papillomavirus vaccine-Drug Profile 96

human papillomavirus vaccine-Drug Profile 97

human papillomavirus vaccine-Drug Profile 98

imiquimod-Drug Profile 99

ingenol mebutate-Drug Profile 100

interferon alfa-2b (recombinant)-Drug Profile 102

interferon alpha-2b (recombinant)-Drug Profile 103

ISANIL-01-Drug Profile 104

PL-202-Drug Profile 105

PP-210-Drug Profile 106

ProCervix-Drug Profile 107

RKP-00156-Drug Profile 109

SB-206-Drug Profile 110

SB105-A10-Drug Profile 111

sinecatechins-Drug Profile 113

Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts-Drug Profile 114

Small Molecules for HPV Infections-Drug Profile 115

Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections-Drug Profile 117

SRT-100-Drug Profile 118

Synthetic Peptides for Viral Infections-Drug Profile 120

Human Papillomavirus Infections-Recent Pipeline Updates 121

Human Papillomavirus Infections-Dormant Projects 129

Human Papillomavirus Infections-Discontinued Products 133

Human Papillomavirus Infections-Product Development Milestones 134

Featured News & Press Releases 134

Appendix 140

Methodology 140

Coverage 140

Secondary Research 140

Primary Research 140

Expert Panel Validation 140

Contact Us 140

Disclaimer 141

List of Tables

Number of Products under Development for Human Papillomavirus Infections, H1 2015 13

Number of Products under Development for Human Papillomavirus Infections-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Human Papillomavirus Infections-Pipeline by 3M Drug Delivery Systems, H1 2015 27

Human Papillomavirus Infections-Pipeline by Admedus Ltd, H1 2015 28

Human Papillomavirus Infections-Pipeline by Agilvax, Inc., H1 2015 29

Human Papillomavirus Infections-Pipeline by Anaconda Pharma, H1 2015 30

Human Papillomavirus Infections-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 31

Human Papillomavirus Infections-Pipeline by Bharat Biotech International Limited, H1 2015 32

Human Papillomavirus Infections-Pipeline by Biogenomics Limited, H1 2015 33

Human Papillomavirus Infections-Pipeline by BioMAS Ltd., H1 2015 34

Human Papillomavirus Infections-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 35

Human Papillomavirus Infections-Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2015 36

Human Papillomavirus Infections-Pipeline by Crucell N.V., H1 2015 37

Human Papillomavirus Infections-Pipeline by Cutanea Life Sciences, H1 2015 38

Human Papillomavirus Infections-Pipeline by EpiPharm AG, H1 2015 39

Human Papillomavirus Infections-Pipeline by FluGen, Inc., H1 2015 40

Human Papillomavirus Infections-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 41

Human Papillomavirus Infections-Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2015 42

Human Papillomavirus Infections-Pipeline by Genticel S.A., H1 2015 43

Human Papillomavirus Infections-Pipeline by Helix BioPharma Corp., H1 2015 44

Human Papillomavirus Infections-Pipeline by Immunservice GmbH, H1 2015 45

Human Papillomavirus Infections-Pipeline by Indian Immunologicals Limited, H1 2015 46

Human Papillomavirus Infections-Pipeline by LEO Pharma A/S, H1 2015 47

Human Papillomavirus Infections-Pipeline by MediGene AG, H1 2015 48

Human Papillomavirus Infections-Pipeline by NanoViricides, Inc., H1 2015 49

Human Papillomavirus Infections-Pipeline by Nielsen Biosciences, Inc., H1 2015 50

Human Papillomavirus Infections-Pipeline by Novan, Inc., H1 2015 51

Human Papillomavirus Infections-Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H1 2015 52

Human Papillomavirus Infections-Pipeline by Spider Biotech, H1 2015 53

Human Papillomavirus Infections-Pipeline by Starpharma Holdings Limited, H1 2015 54

Human Papillomavirus Infections-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 55

Human Papillomavirus Infections-Pipeline by Vaxart, Inc., H1 2015 56

Human Papillomavirus Infections-Pipeline by ViroStatics, srl, H1 2015 57

Assessment by Monotherapy Products, H1 2015 58

Assessment by Combination Products, H1 2015 59

Number of Products by Stage and Target, H1 2015 61

Number of Products by Stage and Mechanism of Action, H1 2015 63

Number of Products by Stage and Route of Administration, H1 2015 65

Number of Products by Stage and Molecule Type, H1 2015 67

Human Papillomavirus Infections Therapeutics-Recent Pipeline Updates, H1 2015 124

Human Papillomavirus Infections-Dormant Projects, H1 2015 132

Human Papillomavirus Infections-Dormant Projects (Contd..1), H1 2015 133

Human Papillomavirus Infections-Dormant Projects (Contd..2), H1 2015 134

Human Papillomavirus Infections-Dormant Projects (Contd..3), H1 2015 135

Human Papillomavirus Infections-Discontinued Products, H1 2015 136

List of Figures

Number of Products under Development for Human Papillomavirus Infections, H1 2015 13

Number of Products under Development for Human Papillomavirus Infections-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Products, H1 2015 22

Assessment by Monotherapy Products, H1 2015 58

Number of Products by Top 10 Targets, H1 2015 60

Number of Products by Stage and Top 10 Targets, H1 2015 60

Number of Products by Top 10 Mechanism of Actions, H1 2015 62

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 62

Number of Products by Top 10 Routes of Administration, H1 2015 64

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 64

Number of Products by Top 10 Molecule Types, H1 2015 66

Number of Products by Stage and Top 10 Molecule Types, H1 2015 66

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3M Drug Delivery Systems

Admedus Ltd

Agilvax, Inc.

Anaconda Pharma

Beijing Minhai Biotechnology Co., Ltd

Bharat Biotech International Limited

Biogenomics Limited

BioMAS Ltd.

Chong Kun Dang Pharmaceutical Corp.

Chongqing Zhifei Biological Products Co., Ltd.

Crucell N.V.

Cutanea Life Sciences

EpiPharm AG

FluGen, Inc.

Foamix Pharmaceuticals Ltd.

G&E Herbal Biotechnology Co., Ltd.

Genticel S.A.

Helix BioPharma Corp.

Immunservice GmbH

Indian Immunologicals Limited

LEO Pharma A/S

MediGene AG

NanoViricides, Inc.

Nielsen Biosciences, Inc.

Novan, Inc.

Shanghai Zerun Biotechnology Co., Ltd.

Spider Biotech

Starpharma Holdings Limited

Takeda Pharmaceutical Company Limited

Vaxart, Inc.

ViroStatics, srl

Human Papillomavirus Infections Therapeutic Products under Development, Key Players in Human Papillomavirus Infections Therapeutics, Human Papillomavirus Infections Pipeline Overview, Human Papillomavirus Infections Pipeline, Human Papillomavirus Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com